Ventyx, Sanofi
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need,
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...
The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
Barclays analyst Emily Field maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €120.00. The ...
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...
Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...
NEW YORK (Reuters) - Sanofi Chief Executive Paul Hudson said on Monday that the company has not made a final decision yet on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback